BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lu Y, Li S, Zhu S, Gong Y, Shi J, Xu L. Methylated DNA/RNA in Body Fluids as Biomarkers for Lung Cancer. Biol Proced Online 2017;19:2. [PMID: 28331435 DOI: 10.1186/s12575-017-0051-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Dvorská D, Braný D, Nagy B, Grendár M, Poka R, Soltész B, Jagelková M, Zelinová K, Lasabová Z, Zubor P, Danková Z. Aberrant Methylation Status of Tumour Suppressor Genes in Ovarian Cancer Tissue and Paired Plasma Samples. Int J Mol Sci 2019;20:E4119. [PMID: 31450846 DOI: 10.3390/ijms20174119] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
2 Li Z, Shu J, Yang B, Zhang Z, Huang J, Chen Y. Emerging non-invasive detection methodologies for lung cancer. Oncol Lett 2020;19:3389-99. [PMID: 32269611 DOI: 10.3892/ol.2020.11460] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Wang Y, Lei L, Zheng YW, Zhang L, Li ZH, Shen HY, Jiang GY, Zhang XP, Wang EH, Xu HT. Odd-skipped related 1 inhibits lung cancer proliferation and invasion by reducing Wnt signaling through the suppression of SOX9 and β-catenin. Cancer Sci 2018;109:1799-810. [PMID: 29660200 DOI: 10.1111/cas.13614] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
4 Vanden Berghe T, Hoste E. Paving the way for precision medicine v2.0 in intensive care by profiling necroinflammation in biofluids. Cell Death Differ 2019;26:83-98. [PMID: 30201975 DOI: 10.1038/s41418-018-0196-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
5 Chen X, Gole J, Gore A, He Q, Lu M, Min J, Yuan Z, Yang X, Jiang Y, Zhang T, Suo C, Li X, Cheng L, Zhang Z, Niu H, Li Z, Xie Z, Shi H, Zhang X, Fan M, Wang X, Yang Y, Dang J, McConnell C, Zhang J, Wang J, Yu S, Ye W, Gao Y, Zhang K, Liu R, Jin L. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nat Commun 2020;11:3475. [PMID: 32694610 DOI: 10.1038/s41467-020-17316-z] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 29.0] [Reference Citation Analysis]
6 Chemi F, Mohan S, Brady G. Circulating Tumour Cells in Lung Cancer. Recent Results Cancer Res 2020;215:105-25. [PMID: 31605226 DOI: 10.1007/978-3-030-26439-0_6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Gai W, Sun K. Epigenetic Biomarkers in Cell-Free DNA and Applications in Liquid Biopsy. Genes (Basel) 2019;10:E32. [PMID: 30634483 DOI: 10.3390/genes10010032] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 17.7] [Reference Citation Analysis]
8 Ramzannezhad A, Hayati A, Bahari A, Najafi-Ashtiani H. Magnetic detection of albuminuria using hematite nanorods synthesized via chemical hydrothermal method. Iran J Basic Med Sci 2021;24:962-8. [PMID: 34712427 DOI: 10.22038/ijbms.2021.53918.12120] [Reference Citation Analysis]
9 Oliver J, Garcia-Aranda M, Chaves P, Alba E, Cobo-Dols M, Onieva JL, Barragan I. Emerging noninvasive methylation biomarkers of cancer prognosis and drug response prediction. Semin Cancer Biol 2021:S1044-579X(21)00062-6. [PMID: 33757849 DOI: 10.1016/j.semcancer.2021.03.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Bouhlel L, Hofman V, Maschi C, Ilié M, Allégra M, Marquette CH, Audigier-Valette C, Thariat J, Hofman P. The liquid biopsy: a tool for a combined diagnostic and theranostic approach for care of a patient with late-stage lung carcinoma presenting with bilateral ocular metastases. Expert Rev Anticancer Ther 2017;17:1087-92. [PMID: 29069959 DOI: 10.1080/14737140.2017.1398089] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
11 Chen B, Li Y, Song R, Xue C, Xu F. Functions of RNA N6-methyladenosine modification in cancer progression. Mol Biol Rep 2019;46:1383-91. [PMID: 30788764 DOI: 10.1007/s11033-018-4471-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
12 Chen B, Li Y, Song R, Xue C, Xu F. Functions of RNA N6-methyladenosine modification in cancer progression. Mol Biol Rep 2019;46:2567-75. [PMID: 30911972 DOI: 10.1007/s11033-019-04655-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
13 Zhang J, Han X, Gao C, Xing Y, Qi Z, Liu R, Wang Y, Zhang X, Yang YG, Li X, Sun B, Tian X. 5-Hydroxymethylome in Circulating Cell-free DNA as A Potential Biomarker for Non-small-cell Lung Cancer. Genomics Proteomics Bioinformatics 2018;16:187-99. [PMID: 30010036 DOI: 10.1016/j.gpb.2018.06.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
14 Schrump DS. Circulating tumor DNA: Solid data from liquid biopsies. J Thorac Cardiovasc Surg 2017;154:1132-3. [PMID: 28629844 DOI: 10.1016/j.jtcvs.2017.05.059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
15 Hofman P. Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology. Cancers (Basel) 2017;9:E154. [PMID: 29125548 DOI: 10.3390/cancers9110154] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
16 Leroy S, Benzaquen J, Mazzetta A, Marchand-Adam S, Padovani B, Israel-Biet D, Pison C, Chanez P, Cadranel J, Mazières J, Jounieaux V, Cohen C, Hofman V, Ilie M, Hofman P, Marquette CH; AIR Project Study Group. Circulating tumour cells as a potential screening tool for lung cancer (the AIR study): protocol of a prospective multicentre cohort study in France. BMJ Open 2017;7:e018884. [PMID: 29282271 DOI: 10.1136/bmjopen-2017-018884] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
17 Xia S, Ye J, Chen Y, Lizaso A, Huang L, Shi L, Su J, Han-Zhang H, Chuai S, Li L, Chen Y. Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patients. Transl Lung Cancer Res 2019;8:1016-28. [PMID: 32010579 DOI: 10.21037/tlcr.2019.12.09] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ren Y, Zhao S, Jiang D, Feng X, Zhang Y, Wei Z, Wang Z, Zhang W, Zhou QF, Li Y, Hou H, Xu Y, Zhou F. Proteomic biomarkers for lung cancer progression. Biomarkers in Medicine 2018;12:205-15. [DOI: 10.2217/bmm-2018-0015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]